Effects of pro-inflammatory cytokines on cannabinoid CB1 and CB2 receptors in immune cells

Acta Physiologica

Volumn 214, Issue 1, 2015, Pages 63-74

  Jean Gilles, L ^a   Braitch, M ^a   Latif, M L ^b   Aram, J ^a   Fahey, A J ^a   Edwards, L J ^a   Robins, R A ^b   Tanasescu, R ^a,c   Tighe, P J ^b   Gran, B ^a   Showe, L C ^d   Alexander, S P ^b   Chapman, V ^b   Kendall, D A ^b   Constantinescu, C S ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^d WISTAR INSTITUTE   (United States)

Author keywords

Cannabinoid receptor 1; Cannabinoid receptor 2; Inflammatory cytokines; Multiple sclerosis; Regulation

Indexed keywords

5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; BETA ACTIN; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RIMONABANT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; BLOOD; BLOOD CELL; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOREACTIVITY; MALE; MULTIPLE SCLEROSIS; NEUTROPHIL; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; T LYMPHOCYTE; UPREGULATION; WESTERN BLOTTING; DRUG EFFECTS; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; YOUNG ADULT;

ADULT; FEMALE; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84927696508     PISSN: 17481708     EISSN: 17481716     Source Type: Journal    
DOI: 10.1111/apha.12474     Document Type: Article

References (55)

1. Alexander, S.P. & Kendall, D.A. 2007. The complications of promiscuity: endocannabinoid action and metabolism. Br J Pharmacol 152, 602-623.
2. Arevalo-Martin, A., Vela, J.M., Molina-Holgado, E., Borrell, J. & Guaza, C. 2003. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J Neurosci 23, 2511-2516.
3. Boothby, M. 2001. Specificity of SN50 for NF-kappa B? Nat Immunol 2, 471-472.
4. Borner, C., Bedini, A., Hollt, V. & Kraus, J. 2008. Analysis of promoter regions regulating basal and interleukin-4-inducible expression of the human CB1 receptor gene in T lymphocytes. Mol Pharmacol 73, 1013-1019.
5. Borner, C., Hollt, V. & Kraus, J. 2012. Mechanisms of the inhibition of nuclear factor-kappaB by morphine in neuronal cells. Mol Pharmacol 81, 587-597.
6. Börner, C., Höllt, V. & Kraus, J. 2007. Activation of human T cells induces upregulation of cannabinoid receptor type 1 transcription. NeuroImmunoModulation 14, 281-286.
7. Compston, A. & Coles, A. 2008. Multiple sclerosis. Lancet 372, 1502-1517.
8. Croxford, J.L. & Miller, S.D. 2003. Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+Win55, 212. J Clin Invest 111, 1231-1240.
9. De Jesus, M.L., Salles, J., Meana, J.J. & Callado, L.F. 2006. Characterization of CB1 cannabinoid receptor immunoreactivity in postmortem human brain homogenates. Neuroscience 140, 635-643.
10. Eljaschewitsch, E., Witting, A., Mawrin, C., Lee, T., Schmidt, P.M., Wolf, S., Hoertnagl, H., Raine, C.S., Schneider-Stock, R., Nitsch, R. & Ullrich, O. 2006. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 49, 67-79.
11. Fahey, A.J., Robins, R.A. & Constantinescu, C.S. 2007. Curcumin modulation of IFN-beta and IL-12 signalling and cytokine induction in human T cells. J Cell Mol Med 11, 1129-1137.
12. Filion, L.G., Graziani-Bowering, G., Matusevicius, D. & Freedman, M.S. 2003. Monocyte-derived cytokines in multiple sclerosis. Clin Exp Immunol 131, 324-334.
13. Galiegue, S., Mary, S., Marchand, J., Dussossoy, D., Carriere, D., Carayon, P., Bouaboula, M., Shire, D., Le Fur, G. & Casellas, P. 1995. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232, 54-61.
14. Grimsey, N.L., Goodfellow, C.E., Scotter, E.L., Dowie, M.J., Glass, M. & Graham, E.S. 2008. Specific detection of CB1 receptors; cannabinoid Cb1 receptor antibodies are not all created equal!. J Neurosci Methods 171, 78-86.
15. Gui, H., Liu, X., Wang, Z.W., He, D.Y., Su, D.F. & Dai, S.M. 2014. Expression of cannabinoid receptor 2 and its inhibitory effects on synovial fibroblasts in rheumatoid arthritis. Rheumatology 53, 802-809.
16. Hemmer, B., Nessler, S., Zhou, D., Kieseier, B. & Hartung, H.P. 2006. Immunopathogenesis and immunotherapy of multiple sclerosis. Nat Clin Pract Neurol 2, 201-211.
17. Jean-Gilles, L., Feng, S., Tench, C.R., Chapman, V., Kendall, D.A., Barrett, D.A. & Constantinescu, C.S. 2009. Plasma endocannabinoid levels in multiple sclerosis. J Neurol Sci 287, 212-215.
18. Jean-Gilles, L., Gran, B. & Constantinescu, C.S. 2010. Interaction between cytokines, cannabinoids and the nervous system. Immunobiology 215, 606-610.
19. Kahl, K.G., Kruse, N., Toyka, K.V. & Rieckmann, P. 2002. Serial analysis of cytokine mRNA profiles in whole blood samples from patients with early multiple sclerosis. J Neurol Sci 200, 53-55.
20. Katona, S., Kaminski, E., Sanders, H. & Zajicek, J. 2005. Cannabinoid influence on cytokine profile in multiple sclerosis. Clin Exp Immunol 140, 580-585.
21. Kavia, R., De Ridder, D., Constantinescu, C., Stott, C. & Fowler, C. 2010. Randomized controlled trial of sativex to treat detrusor overactivity in multiple sclerosis. Mult Scler 16, 1349-1359.
22. Kazanecki, C.C., Uzwiak, D.J. & Denhardt, D.T. 2007. Control of osteopontin signaling and function by post-translational phosphorylation and protein folding. J Cell Biochem 102, 912-924.
23. Klein, T.W., Newton, C.A., Nakachi, N. & Friedman, H. 2000. Delta 9-tetrahydrocannabinol treatment suppresses immunity and early IFN-gamma, IL-12, and IL-12 receptor beta 2 responses to Legionella pneumophila infection. J Immunol 164, 6461-6466.
24. Kleine, T.O., Zwerenz, P., Graser, C. & Zofel, P. 2003. Approach to discriminate subgroups in multiple sclerosis with Cerebrospinal Fluid (CSF) basic inflammation indices and TNF-alpha, IL-1beta, IL-6, IL-8. Brain Res Bull 61, 327-346.
25. Kurtzke, J.F. 1983. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 33, 1444-1452.
26. Ledeboer, A., Gamanos, M., Lai, W., Martin, D., Maier, S.F., Watkins, L.R. & Quan, N. 2005. Involvement of spinal cord nuclear factor kappab activation in rat models of proinflammatory cytokine-mediated pain facilitation. Eur J Neurosci 22, 1977-1986.
27. Loría, F., Petrosino, S., Mestre, L., Spagnolo, A., Correa, F., Hernangómez, M., Guaza, C., Di Marzo, V. & Docagne, F. 2008. Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. Eur J Neurosci 28, 633-641.
28. Lou, Z.Y., Chen, C., He, Q., Zhao, C.B. & Xiao, B.G. 2011. Targeting CB2 receptor as a neuroinflammatory modulator in experimental autoimmune encephalomyelitis. Mol Immunol 49, 453-461.
29. Lou, Z.Y., Zhao, C.B. & Xiao, B.G. 2012. Immunoregulation of experimental autoimmune encephalomyelitis by the selective CB1 receptor antagonist. J Neurosci Res 90, 84-95.
30. Malamud, V., Vaaknin, A., Abramsky, O., Mor, M., Burgess, L.E., Ben-Yehudah, A. & Lorberboum-Galski, H. 2003. Tryptase activates peripheral blood mononuclear cells causing the synthesis and release of TNF-alpha, IL-6 and IL-1 beta: possible relevance to multiple sclerosis. J Neuroimmunol 138, 115-122.
31. Maresz, K., Carrier, E.J., Ponomarev, E.D., Hillard, C.J. & Dittel, B.N. 2005. Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem 95, 437-445.
32. Molina-Holgado, E., Vela, J.M., Arévalo-Martín, A., Almazán, G., Molina-Holgado, F., Borrell, J. & Guaza, C. 2002. Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/AKT signaling. J Neurosci 22, 9742-9753.
33. Nunez, E., Benito, C., Pazos, M.R., Barbachano, A., Fajardo, O., Gonzalez, S., Tolon, R.M. & Romero, J. 2004. Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study. Synapse 53, 208-213.
34. Persson, P.B. 2013. Good publication practice in physiology guidelines. Acta Physiol 209, 250-253.
35. Pertwee, R.G. 2002. Cannabinoids and multiple sclerosis. Pharmacol Ther 95, 165-174.
36. Pertwee, R.G. 2010. Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr Med Chem 17, 1360-1381.
37. Pryce, G., Ahmed, Z., Hankey, D.J., Jackson, S.J., Croxford, J.L., Pocock, J.M., Ledent, C., Petzold, A., Thompson, A.J., Giovannoni, G., Cuzner, M.L. & Baker, D. 2003. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 126, 2191-2202.
38. Racz, I., Nadal, X., Alferink, J., Banos, J.E., Rehnelt, J., Martin, M., Pintado, B., Gutierrez-Adan, A., Sanguino, E., Bellora, N., Manzanares, J., Zimmer, A. & Maldonado, R. 2008. Interferon-gamma is a critical modulator of CB(2) cannabinoid receptor signaling during neuropathic pain. J Neurosci 28, 12136-12145.
39. Ramil, E., Sanchez, A.J., Gonzalez-Perez, P., Rodriguez-Antiguedad, A., Gomez-Lozano, N., Ortiz, P., Arroyo, R., De las Heras, V., Vilches, C. & Garcia-Merino, A. 2010. The Cannabinoid Receptor 1 Gene (CNR1) and multiple sclerosis: an association study in two case-control groups from Spain. Mult Scler 16, 139-146.
40. Rieder, S.A., Chauhan, A., Singh, U., Nagarkatti, M. & Nagarkatti, P. 2010. Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. Immunobiology 215, 598-605.
41. Roche, M., Kelly, J.P., O'Driscoll, M. & Finn, D.P. 2008. Augmentation of endogenous cannabinoid tone modulates lipopolysaccharide- induced alterations in circulating cytokine levels in rats. Immunology 125, 263-271.
42. Rog, D.J. 2010. Cannabis-based medicines in multiple sclerosis - a review of clinical studies. Immunobiology 215, 658-672.
43. Rossi, S., Bozzali, M., Bari, M., Mori, F., Studer, V., Motta, C., Buttari, F., Cercignani, M., Gravina, P., Mastrangelo, N. etal. 2013. Association between a genetic variant of type-1 cannabinoid receptor and inflammatory neurodegeneration in multiple sclerosis. PLoS One 8, e82848.
44. Rubio-Araiz, A., Arevalo-Martin, A., Gomez-Torres, O., Navarro-Galve, B., Garcia-Ovejero, D., Suetterlin, P., Sanchez-Heras, E., Molina-Holgado, E. & Molina-Holgado, F. 2008. The endocannabinoid system modulates a transient TNF pathway that induces neural stem cell proliferation. Mol Cell Neurosci 38, 374-380.
45. Sagar, D.R., Kelly, S., Millns, P.J., O'Shaughnessey, C.T., Kendall, D.A. & Chapman, V. 2005. Inhibitory effects of CB1 and CB2 receptor agonists on responses of DRG neurons and dorsal horn neurons in neuropathic rats. Eur JNeurosci 22, 371-379.
46. Sanchez Lopez, A.J., Roman-Vega, L., Ramil Tojeiro, E., Giuffrida, A. & Garcia-Merino, A. 2015. Regulation of cannabinoid receptor gene expression and endocannabinoid levels in lymphocyte subsets by IFN-beta: a longitudinal study in multiple sclerosis patients. Clin Exp Immunol 179, 119-127.
47. Sheng, W.S., Hu, S., Min, X., Cabral, G.A., Lokensgard, J.R. & Peterson, P.K. 2005. Synthetic cannabinoid win 55, 212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. Glia 49, 211-219.
48. Siegling, A., Hofmann, H.A., Denzer, D., Mauler, F. & De Vry, J. 2001. Cannabinoid CB(1) receptor upregulation in a rat model of chronic neuropathic pain. Eur J Pharmacol 415, R5-R7.
49. Stella, N. 2009. Endocannabinoid signaling in microglial cells. Neuropharmacology 56, 244-253.
50. Tanasescu, R. & Constantinescu, C.S. 2010. Cannabinoids and the immune system: an overview. Immunobiology 215, 588-597.
51. Upham, B.L., Rummel, A.M., Carbone, J.M., Trosko, J.E., Ouyang, Y., Crawford, R.B. & Kaminski, N.E. 2003. Cannabinoids inhibit gap junctional intercellular communication and activate ERK in a rat liver epithelial cell line. Int J Cancer 104, 12-18.
52. Woolmore, J., Stone, M., Holley, S., Jenkinson, P., Ike, A., Jones, P., Fryer, A., Strange, R., Stephens, R., Langdon, D. & Hawkins, C. 2008. Polymorphisms of the cannabinoid 1 receptor gene and cognitive impairment in multiple sclerosis. Mult Scler 14, 177-182.
53. Xu, W., Filppula, S.A., Mercier, R., Yaddanapudi, S., Pavlopoulos, S., Cai, J., Pierce, W.M. & Makriyannis, A. 2005. Purification and mass spectroscopic analysis of human CB1 cannabinoid receptor functionally expressed using the baculovirus system. J Pept Res 66, 138-150.
54. Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A. & Thompson, A. 2003. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (cams study): multicentre randomised placebo-controlled trial. Lancet 362, 1517-1526.
55. Zheng, D., Bode, A.M., Zhao, Q., Cho, Y.Y., Zhu, F., Ma, W.Y. & Dong, Z. 2008. The cannabinoid receptors are required for ultraviolet-induced inflammation and skin cancer development. Cancer Res 68, 3992-3998.